Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use Surveillance of Cabometyx in Hepatocellular Carcinoma
jRCT2031210403Completed
- Sponsor
- Takeda
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Takeda. Primary endpoints: Adverse events related to hepatic failure, hepatic dysfunction, and pancreatitis, Serious adverse events and 2 more. Started Nov 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210403.